BCL2L1 and Miyoshi myopathy: In another trial (NCT01794520), the benefit from ABT-199/BZB for relapsed/refractory MM patients was associated with high BCL-2 expression (i.e. BCL-2/BCL-xL or BCL-2/MCL-1 ratio): 12 out of the 14 patients with t(11:14) translocation, which correlates with enhanced BCL-2 expression, showed a positive response18.